CYTK Q3 2021 Earnings — Cytokinetics, Incorporated Revenue & Financial Results | Market Cap Arena

CYTKCytokinetics, Incorporated

$8B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M-87.0% YoY

Gross Profit

-$43M-790.9% margin

Operating Income

-$69M-1272.8% margin

Net Income

-$76M-1399.4% margin

EPS (Diluted)

$-0.95

QoQ Revenue Growth

+91.2%

Cash Flow

Operating Cash Flow

-$39M

Free Cash Flow

-$54M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$828M

Total Liabilities

$579M

Stockholders' Equity

$249M

Cash & Equivalents

$91M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$42M	-87.0%
Gross Profit	-$43M	$17M	-345.9%
Operating Income	-$69M	$5M	-1434.9%
Net Income	-$76M	-$3M	-2296.4%

Revenue Segments

Milestones

$5M92%

Research And Development

$437,0008%